http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112538063-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fb38ebd40c70e97cc5f1519c6699162 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5934bbc5366931812eaa948c30e918fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f9685f05a8debc5afb4f365e6299106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_819c436a36f361d3534fb45c58c58c7d |
| publicationDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112538063-A |
| titleOfInvention | A kind of MCL-1 inhibitor and its preparation method and application |
| abstract | The invention discloses an MCL-1 inhibitor and a preparation method and application thereof. In the present invention, compound B is obtained by reacting ethylene oxalate with compound A including naphthoethyl ketone for 4 to 6 hours, and then reacting with compound C including 3-hydroxyisobenzofuran-1(3H)-ketone to obtain compound D, Compound D is dissolved in 10～15mL of sodium hydroxide aqueous solution with a mass concentration of 40% and the reaction is finished, and compound E is obtained through pH adjustment, extraction, evaporation to dryness and recrystallization. -Dimethylpropylamine) carbodiimide, 1-hydroxybenzotriazole, and the o-toluidine containing halogen substituents are subjected to washing and solid recrystallization to obtain MCL-1 inhibitor. The MCL-1 inhibitor of the present invention can be used as a tumor therapeutic drug, or when used in combination with the BCL-2 inhibitor venetoclax, it can produce the effect of a sensitizer of a BCL-2 inhibitor, and can also produce a drug-receiving body. Efficacy of reversal agents for resistance to venetoclax. |
| priorityDate | 2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.